LONDON, December 8, 2016 /PRNewswire/ --
The Economist Events' second annual War on Cancer 2016, held in
London on Tuesday, was host to
some of the highest profile leaders in oncology from across the
field and around Europe.
Discussions at the summit explored innovative approaches to cancer
prevention and treatment, solutions to overcome shortcomings in
delivery and examples of best practice and opportunities for
cross-sectoral collaboration.
The event gathered over 150 global influencers, government
ministers, private sector CEOs, academia, healthcare professionals
and high-level national and international media from around
Europe.
Andreas Penk, regional
president oncology,
international developed
markets, Pfizer commented: "We see more and more
possibilities on the horizon to cure specific cancers. Personalized
medicine and immuno-oncology will lead the way and bridge until the
next generation of medicine is ready. Curing is a game changer. All
involved parties should start to work together on innovative
solutions in care, contracting, pricing, and regulatory to make
sure we translate the possible into reality."
Mahiben Maruthappu, co-founder, NHS Innovation
Accelerator, said: " Whilst great technological
advancements have already been made in the war against cancer, it
is of great importance that research and development continues in
order to continue to deliver innovative new treatments.This
event provides a platform for global leaders
from across the industry to discuss what the future might hold
and ensure health care systems are prepared."
Speakers offered contrasting and thought-provoking commentary on
how to deal with the most pressing of sector trends leading to
lively debate amongst the delegates. Topics covered included
optimising national cancer control plans, cancer in the context of
health care systems, the promise and peril of health-tech
convergence and mobilising action and inspiring change.
Key speakers at the summit
included:
- Matti Aapro,
board member, European Cancer
Organisation
- Cary
Adams,chief executive
officer, Union for International Cancer Control
- Tit Albreht, coordinator, Cancer Control
Joint Action (CanCon);head, National Institute of
Public Health of Slovenia
- Kathi Apostolidis,
vice-president, European Cancer Patient Coalition
(ECPC); president of Executive Committee, Hellenic
Cancer Federation - ELL.O.K
- Frauke Becker,
research associate, Institute of Health and
Society, Newcastle
University
- John
Bell, regius professor
of medicine, University of
Oxford; chairman, Office for Strategic
Coordination of Health Research (OSCHR)
- Jurgi Camblong,chief
executive officer and
co-founder, Sophia Genetics
- Josep
Figueras, director, European Observatory
on Health Systems and Policies; head, World Health
Organization European Centre on Health Policy
- George Freeman,
member oparliament for Mid Norfolk and
chair, Prime Minister's Policy
Board
- David
Khayat, head of the
department of Oncology, Pitié-Salpêtrière Hospital
and professor of Oncology, University Pierre and
Marie Curie
- Bryony Kimmings, creator of the musical
'A Pacifist's Guide to the War on
Cancer'
- Jane Maher,
chief medical officer,
Macmillan Cancer Support
- Lydia Makaroff,
director, European Cancer Patient Coalition
- Mahiben Maruthappu, co-founder, NHS Innovation
Accelerator
- Maya Martinez -
Davis, senior vice-president, Global
Head of Oncology Franchise, Merck KGaA
- Vivek
Muthu, chair, Economist Intelligence Unit
Healthcare
- Annie Pannelay, healthcare
principal, Economist Intelligence Unit
- Terje
Peetso,policy officer,
directorate-general
communications networks,
content and technology, European
Commission
- Andreas Penk, regional
president oncology,
international developed
markets, Pfizer
- Jem Rashbass, national director
for disease registration, Public Health
England
- Gunnar
Saeter, professor and head
of institute, Institute for Cancer Research - Olso
University Hospital
- Katherine Smith,
reader- global public
health unit, University of Edinburgh
- Zhen Su,
vice-president, US Oncology Medical Affairs, EMD
Serono
- Richard Sullivan,
professor of cancer and
global health, King's College
London; Director, Institute of Cancer Policy
- Frans van
Houten, chief executive
and chairman, Philips
- Paul
Workman,chief executive
officer and president, The Institute of
Cancer Research London; Harrap Professor of Pharmacology and
Therapeutics
Tweet via @EconomistEvents #WaronCancer
Press enquiries
Lindsey Neville
Email: waroncancer2016@consilium-comms.com
Tel: +44 (0)20 3709 5700
-ENDS-
For general queries or further information about the event please
call +44 (0) 207 576 8118 or e-mail emeaevents@economist.com
Want more from The Economist Events?
Join us on Twitter: @EconomistEvents
About The Economist Events
The Economist Events' philosophy is to tackle issues with a
forward-looking, uniquely global perspective. We aim to create
events for the intellectually curious: people who enjoy ideas and
who are passionate about the issues that define our world.
Attend our events:
http://www.economist.com/events-conferences/emea
Founding sponsor: Bristol-Myers Squibb
Bristol-Myers Squibb is a global
biopharmaceutical company whose mission is to discover, develop and
deliver innovative medicines that help patients prevail over
serious diseases. We are committed to changing survival
expectations in hard-to-treat cancers and the way patients live
with cancer through our pioneering, comprehensive Immuno-Oncology
portfolio and clinical program as well as research collaborations
with academia and biotech companies.
Founding sponsor: Merck
Merck discovers, develops, manufactures and markets prescription
medicines of both chemical and biological origin in specialist
indications. We have an enduring commitment to deliver novel
therapies in our core focus areas including oncology and
immuno-oncology; supporting patients with cancer. Merck has a
robust pipeline of potential therapies in oncology, immuno-oncology
and immunology.
Gold sponsor: Pfizer Oncology
Pfizer Oncology is focused on helping to redefine life with cancer.
By maximizing our internal scientific resources and collaborating
with other companies, government and academic institutions, we
bring together the brightest and most enterprising minds to take on
the toughest cancers, helping speed breakthrough treatments to
patients around the world.
Silver Sponsor: Novartis
Novartis Oncology is a global leader in providing a broad range of
innovative therapies to help improve the lives of cancer
patients.
Silver Sponsor: Varian Medical Systems
Global manufacturer of medical devices and software for treating
cancer with radiotherapy, radiosurgery, proton therapy and
brachytherapy.
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in providing
trusted, healthcare-focused strategic IR and financial PR counsel
to corporations, Boards, senior decision makers and executives.
From offices in Europe and
USA, Consilium Strategic
Communications' senior team provides cross-border comprehensive
financial and corporate healthcare communications advice to some of
the world's most prominent corporations around-the-clock. For more
information, please visit our website at
http://www.consilium-comms.com